Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23922209 | 0.93 | TRIM24 (0.38) | TRIM24TRIM33CYP2B6ALDH1A1 | |
| SCHEMBL14564468 | 0.91 | TRIM24 (0.40) | TRIM24TRIM33CYP2B6ALDH1A1 | |
| SCHEMBL2351392 | 0.86 | LMNA (0.32) | ALDH1A1LMNAMAPT | |
| SCHEMBL2015273 | 0.82 | TRIM24 (0.39) | BRD4BRD2TRIM24TRIM33ALDH1A1 | |
| SCHEMBL2636601 | 0.75 | — | — | |
| SCHEMBL16130222 | 0.73 | CYP2B6 (0.32) | CYP2B6 | |
| SCHEMBL141779 | 0.70 | LMNA (0.34) | TRIM24TRIM33ALDH1A1LMNAMAPT | |
| SCHEMBL17898501 | 0.70 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4772906 | 0.70 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL4400626 | 0.69 | CYP2B6 (0.42) | CYP2B6ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-11148998-B2 | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
| EP-2155676-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | Commissariat à l'Energie Atomique (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100041243-A1 | Precursors for Depositing Silicon-containing Films and Methods for Making and Using Same | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2154141-A2 | Precursors for depositing silicon-containing films and methods for making and using same | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1554256-A4 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1554256-A1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | Merck & Co., Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004007468-A1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | HRH4, HRH3, HRH2 | BRD4 119/4885BRD2 579/4885TRIM24 3937/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | BRD4 1582/4885BRD2 1231/4885TRIM24 3680/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | BRD4 281/4885BRD2 248/4885TRIM24 3724/4885 |
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | BRD4 4738/4885BRD2 4827/4885TRIM24 3939/4885 |
| US-11148998-B2 | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof | RARB, RXRB, RXRA | BRD4 608/4885BRD2 820/4885TRIM24 1402/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | BRD4 1230/4885BRD2 2118/4885TRIM24 4060/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | BRD4 503/4885BRD2 805/4885TRIM24 2701/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | BRD4 532/4885BRD2 2264/4885TRIM24 3138/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | BRD4 4738/4885BRD2 4827/4885TRIM24 3939/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | BRD4 540/4885BRD2 1383/4885TRIM24 2265/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | BRD4 116/4885BRD2 449/4885TRIM24 4053/4885 |
| US-20100041243-A1 | Precursors for Depositing Silicon-containing Films and Methods for Making and Using Same | PNISR, MSRB3, MSR1 | BRD4 1599/4885BRD2 1234/4885TRIM24 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.